Neurobiology of Opioid Dependence: 2 - 2

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT00000193
First received: September 20, 1999
Last updated: September 26, 2013
Last verified: September 2013
  Purpose

The purpose of this study is to evaluate the effects of gamma hydroxybutyric on naloxone-precipitated opiate withdrawal.


Condition Intervention Phase
Opioid-Related Disorders
Drug: Gamma hydroxybutyric
Phase 2

Study Type: Interventional
Study Design: Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Neurobiology of Opioid Dependence: 2

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Behavioral, subjective, measures of naloxone-preci
  • Phsyiological, neuroendocrine measures of naloxone

Enrollment: 0
Study Start Date: January 1993
Study Completion Date: January 1998
Primary Completion Date: January 1998 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000193

Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
Investigators
Principal Investigator: Marc I Rosen, M.D. VA Connecticut Healthcare System
  More Information

No publications provided

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000193     History of Changes
Other Study ID Numbers: NIDA-00191-2, K20DA000191, K20-00191-2
Study First Received: September 20, 1999
Last Updated: September 26, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 18, 2014